Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.61 |
| ▸ | FBP1 | P09467 | 2/20 | 0.61 |
| ▸ | GAK | O14976 | 4/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.58 |
| ▸ | RIPK2 | O43353 | 3/20 | 0.58 |
| ▸ | BUB1 | O43683 | 3/20 | 0.58 |
| ▸ | STK10 | O94804 | 3/20 | 0.58 |
| ▸ | MAP3K1 | Q13233 | 3/20 | 0.58 |
| ▸ | PIP4K2C | Q8TBX8 | 2/20 | 0.58 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.58 |
| ▸ | AURKA | O14965 | 2/20 | 0.58 |
| ▸ | ABL1 | P00519 | 2/20 | 0.58 |
| ▸ | LCK | P06239 | 2/20 | 0.58 |
| ▸ | LYN | P07948 | 2/20 | 0.58 |
| ▸ | RET | P07949 | 2/20 | 0.58 |
| ▸ | SRC | P12931 | 2/20 | 0.58 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.58 |
| ▸ | FECH | P22830 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL256396 | 0.80 | EGFR (0.69) | EGFRFBP1GAKALDH1A1MAPT | |
| SCHEMBL1507688 | 0.80 | EGFR (0.71) | EGFRFBP1GAKALDH1A1MAPT | |
| SCHEMBL1507566 | 0.80 | FBP1 (0.74) | EGFRFBP1GAKALDH1A1MAPT | |
| SCHEMBL12426823 | 0.79 | EGFR (0.69) | EGFRFBP1GAKALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL3873473 | 0.79 | EGFR (0.67) | EGFRFBP1GAKALDH1A1MAPT | |
| SCHEMBL1507686 | 0.79 | FBP1 (0.64) | EGFRFBP1GAKALDH1A1MAPT | |
| Erlotinib SCHEMBL2034496 | 0.78 | EGFR (0.87) | EGFRFBP1GAKALDH1A1MAPT | |
| SCHEMBL1507752 | 0.78 | FBP1 (0.60) | EGFRFBP1GAKALDH1A1MAPT | |
| SCHEMBL28407487 | 0.78 | EGFR (0.69) | EGFRFBP1GAKALDH1A1MAPT | |
| SCHEMBL4356364 | 0.78 | EGFR (0.69) | EGFRFBP1GAKALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012028861-A1 | PURE ERLOTINIB | GENERICS [UK] LIMITED (GB) | 2012-03-08 | — | — | WO | disclosed |
| US-7960545-B2 | Process for the prepartion of erlotinib | NATCO PHARMA LIMITED (IN) | 2011-06-14 | — | — | US | disclosed |
| US-20090306377-A1 | NOVEL PROCESS FOR THE PREPARTION OF ERLOTINIB | NATCO PHARMA LIMITED (IN) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306377-A1 | NOVEL PROCESS FOR THE PREPARTION OF ERLOTINIB | ERBB4, ABL1, KRAS | EGFR 4/4885FBP1 2558/4885GAK 889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.